VIENNA (Reuters) - Patients switching from Pfizer's branded cholesterol pill Lipitor to Merck & Co's Zocor -- now available as a cheap generic -- are more likely to have a heart attack or die, according to a Pfizer-backed study.
The findings, which were based on observations from a primary case database in Britain, were presented at the annual European Society of Cardiology congress on Wednesday and will fuel controversy about drug switching.
